Transmedics Group Inc (NASDAQ: TMDX)’s stock price has dropped by -4.26 in relation to previous closing price of 150.98. Nevertheless, the company has seen a loss of -14.47% in its stock price over the last five trading days. zacks.com reported 2024-08-30 that Does TransMedics (TMDX) have what it takes to be a top stock pick for momentum investors? Let’s find out.
Is It Worth Investing in Transmedics Group Inc (NASDAQ: TMDX) Right Now?
The price-to-earnings ratio for Transmedics Group Inc (NASDAQ: TMDX) is above average at 4048.77x. The 36-month beta value for TMDX is also noteworthy at 2.01. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for TMDX is 32.21M, and at present, short sellers hold a 18.83% of that float. The average trading volume of TMDX on September 05, 2024 was 745.67K shares.
TMDX’s Market Performance
TMDX’s stock has seen a -14.47% decrease for the week, with a -7.40% drop in the past month and a 7.00% gain in the past quarter. The volatility ratio for the week is 5.01%, and the volatility levels for the past 30 days are at 4.99% for Transmedics Group Inc The simple moving average for the last 20 days is -12.78% for TMDX’s stock, with a simple moving average of 31.64% for the last 200 days.
Analysts’ Opinion of TMDX
Many brokerage firms have already submitted their reports for TMDX stocks, with Needham repeating the rating for TMDX by listing it as a “Buy.” The predicted price for TMDX in the upcoming period, according to Needham is $208 based on the research report published on August 21, 2024 of the current year 2024.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see TMDX reach a price target of $161. The rating they have provided for TMDX stocks is “Overweight” according to the report published on June 06th, 2024.
Stephens gave a rating of “Overweight” to TMDX, setting the target price at $151 in the report published on June 04th of the current year.
TMDX Trading at -6.50% from the 50-Day Moving Average
After a stumble in the market that brought TMDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.51% of loss for the given period.
Volatility was left at 4.99%, however, over the last 30 days, the volatility rate increased by 5.01%, as shares sank -0.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.91% lower at present.
During the last 5 trading sessions, TMDX fell by -14.41%, which changed the moving average for the period of 200-days by +116.70% in comparison to the 20-day moving average, which settled at $165.66. In addition, Transmedics Group Inc saw 83.13% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TMDX starting from Corcoran Nicholas, who sale 10,000 shares at the price of $176.02 back on Aug 27 ’24. After this action, Corcoran Nicholas now owns 21,105 shares of Transmedics Group Inc, valued at $1,760,200 using the latest closing price.
Corcoran Nicholas, the Officer of Transmedics Group Inc, proposed sale 10,000 shares at $176.02 during a trade that took place back on Aug 27 ’24, which means that Corcoran Nicholas is holding shares at $1,760,158 based on the most recent closing price.
Stock Fundamentals for TMDX
Current profitability levels for the company are sitting at:
- -0.0 for the present operating margin
- 0.61 for the gross margin
The net margin for Transmedics Group Inc stands at 0.01. The total capital return value is set at -0.0. Equity return is now at value 1.79, with 0.41 for asset returns.
Based on Transmedics Group Inc (TMDX), the company’s capital structure generated 0.73 points at debt to capital in total, while cash flow to debt ratio is standing at 0.05. The debt to equity ratio resting at 2.69. The interest coverage ratio of the stock is -0.06.
Currently, EBITDA for the company is 8.76 million with net debt to EBITDA at 9.1. When we switch over and look at the enterprise to sales, we see a ratio of 13.81. The receivables turnover for the company is 4.42for trailing twelve months and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.37.
Conclusion
In summary, Transmedics Group Inc (TMDX) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
